| Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study (NCT06463626) | Novartis | 2020-04-06 |
| PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (NCT03809988) | MedSIR | 2019-04-05 |
| WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor (NCT03854903) | Georgetown University | 2019-04-01 |
| A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer (NCT03854617) | Chinese Academy of Medical Sciences | 2019-02-20 |
| Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer (NCT02668666) | Oana Danciu, MD | 2017-02-01 |
| Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (NCT02894398) | iOMEDICO AG | 2016-09-06 |
| Palbociclib With Everolimus + Exemestane In BC (NCT02871791) | Dana-Farber Cancer Institute | 2016-08-24 |
| ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism (NCT02806817) | Centro Nacional de Investigaciones Oncologicas CARLOS III | 2016-07-01 |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (NCT02824575) | Montefiore Medical Center | 2016-07-01 |
| A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older (NCT02823262) | Beth Israel Deaconess Medical Center | 2016-07-01 |
| A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (NCT02623972) | Dana-Farber Cancer Institute | 2016-02-26 |
| Patterns of Prescribing and Monitoring of Palbociclib (NCT03285568) | Rush University Medical Center | 2015-02-03 |
| Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients (NCT02175446) | Consorzio Oncotech | 2014-09-01 |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (NCT01905592) | Tesaro, Inc. | 2014-02-25 |
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer (NCT01918306) | Vanderbilt-Ingram Cancer Center | 2013-09-01 |
| Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer (NCT01548677) | European Organisation for Research and Treatment of Cancer - EORTC | 2013-04-01 |
| Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients (NCT01779531) | Guangdong Academy of Medical Sciences | 2013-01-01 |
| Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer (NCT01394211) | University of Arizona | 2011-07-13 |
| Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer (NCT01288261) | University of Arizona | 2011-01-01 |
| 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer (NCT01935492) | Borstkanker Onderzoek Groep | 2010-11-01 |
| Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients (NCT01885013) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2010-09-01 |